Open Orphan PLC Change in Registered Office (7361E)

TIDMORPH

RNS Number : 7361E

Open Orphan PLC

02 March 2020

2 March 2020

Open Orphan plc

("Open Orphan", or the "Company")

Change in Registered Office

Open Orphan , the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services , announces that the Company is moving its registered office and that, with effect from today, the registered office address will change to Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX.

For further information please contact:

 
                                                     +353 (0)1 644 
 Open Orphan plc                                      0007 
  Cathal Friel, Executive Chairman                    +44 (0)20 7347 
  Trevor Phillips, Chief Executive Officer            5350 
 
 Arden Partners plc (Nominated Adviser and Joint 
  Broker)                                           +44 (0)20 7614 
  John Llewellyn-Lloyd / Benjamin Cryer              5900 
 
 Davy (Euronext Growth Adviser and Joint Broker)    +353 (0)1 679 
  Anthony Farrell                                    6363 
 
 Camarco (Financial PR) 
                                                    +44 (0)20 3757 
 Tom Huddart / Daniel Sherwen                        4980

Notes to Editors:

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.

Open Orphan comprises of two commercial specialist CRO services businesses (Venn and hVIVO) and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CROKKBBBPBKDQNK

(END) Dow Jones Newswires

March 02, 2020 10:25 ET (15:25 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024